Evaluating the Unmet Needs of Older Adults to Promote Functional Recovery After a Critical Illness (LANTERN)

January 25, 2024 updated by: Yale University
This is a prospective longitudinal study that will evaluate the unmet needs of older adults (65 and older) who return home (either directly or after short-term rehab) after an ICU hospitalization, evaluate the association of these unmet needs with clinically relevant outcomes, and assess barriers and facilitators to addressing these unmet needs. The proposed research will inform the development and evaluation of a subsequent intervention to improve functional outcomes among older ICU survivors, in alignment with the NIH's mission to reduce disability.

Study Overview

Status

Recruiting

Detailed Description

To identify unmet needs in multiple domains after return home from an ICU hospitalization, evaluate whether these unmet needs are associated with disability burden in the subsequent 6 months, and ascertain whether these associations are moderated by initial discharge destination (home or STR).

Study Type

Observational

Enrollment (Estimated)

650

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Connecticut
      • New Haven, Connecticut, United States, 06520
        • Recruiting
        • Yale New Haven Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Community-dwelling older adults who return home (either directly or after a stay in short-term rehab (STR)) after an ICU hospitalization.

Description

Inclusion Criteria:

PARTICIPANTS

  • Age ≥ 65 years
  • Survived an ICU admission of ≥2 days

CAREGIVERS

  • Age ≥ 18 years
  • Identified as caregiver of LANTERN participant who is an informal (unpaid) caregiver.

Exclusion Criteria:

PARTICIPANTS

  • Advance directive of comfort measures only (CMO) or a transition to hospice
  • Planned discharge to a location other than home or Short-Term Rehab
  • Tracheostomy with ventilator dependence
  • Severe acute or prior neurologic injury (such as anoxic brain injury or acute, massive stroke)
  • Advanced dementia
  • ICU admission for monitoring only (e.g., antibiotic desensitization)
  • Primary language other than English.

CAREGIVERS

  • Primary language other than English
  • Is a paid caregiver
  • Unwilling to complete a qualitative interview

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Older adults returning home post-ICU
Community-dwelling older adults who return home (either directly or after a stay in short-term rehab (STR)) after an ICU hospitalization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disability Count
Time Frame: monthly up to 6 months
Number of instances of disability during activities of daily living (ADLs), instrumental activities of daily living (IADLs), and mobility activity. Disability is defined as an inability to complete the task or the need for personal assistance to complete the task. The higher the count, the more disability.
monthly up to 6 months
Number of hospital readmissions
Time Frame: monthly up to 6 months
Number of hospital readmissions monthly up to 6 months.
monthly up to 6 months
Number of deaths
Time Frame: monthly up to 6 months
Number of deaths each month up to 6 months.
monthly up to 6 months
Barriers and Facilitators to addressing unmet needs
Time Frame: month 6
Barriers and facilitators to addressing unmet needs will be assessed using qualitative interviews. A subgroup of participants will receive qualitative interviews conducted with members of the study team. Content analysis will then be used to identify barriers and facilitators to addressing unmet needs that will be informative when planning a future intervention.
month 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional non-recovery
Time Frame: monthly up to 6 months
Not returning to the pre-ICU functional baseline within the follow-up period
monthly up to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Lauren Ferrante, MD, MHS, Yale School of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 25, 2024

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

October 1, 2028

Study Registration Dates

First Submitted

August 15, 2023

First Submitted That Met QC Criteria

August 15, 2023

First Posted (Actual)

August 23, 2023

Study Record Updates

Last Update Posted (Estimated)

January 29, 2024

Last Update Submitted That Met QC Criteria

January 25, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2000034943
  • 1R01AG079916-01A1 (U.S. NIH Grant/Contract: NIH)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified data from this study will be available to investigators who sign a Data Use Agreement (DUA) executed between Yale University and the investigator's institution. The DUA requires the investigators to attest to (1) their commitment to using the data only for approved research purposes and not to identify any individual human participant; (2) their commitment to securing the data using appropriate computer technology; and (3) their commitment to destroying or returning the data after analyses are completed.

Data will not be available until all analyses are complete.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness

3
Subscribe